Antonio Sorlozano1, Antonio Jimenez-Pacheco2, Juan de Dios Luna Del Castillo3, Antonio Sampedro4, Antonio Martinez-Brocal4, Consuelo Miranda-Casas4, José María Navarro-Marí4, José Gutiérrez-Fernández5. 1. Department of Microbiology, School of Medicine, University of Granada, Granada, Spain. 2. Department of Urology, Santa Ana Hospital, Motril, Spain. 3. Department of Statistics and Operation Research, University of Granada, Granada, Spain. 4. Department of Microbiology, Virgen de las Nieves University Hospital, Granada, Spain. 5. Department of Microbiology, School of Medicine, University of Granada, Granada, Spain; Department of Microbiology, Virgen de las Nieves University Hospital, Granada, Spain. Electronic address: josegf@ugr.es.
Abstract
BACKGROUND: We conducted a retrospective analysis on the identification and antibiogram of all bacteria isolated from urine samples with microbiological confirmation of urinary tract infection (UTI) in a Spanish reference hospital over a 7-year period. METHODS: A retrospective analysis was performed of the identification and antibiogram data. RESULTS: A total of 31,758 uropathogens were isolated. Escherichia coli accounted for the majority (55.2%) of these, followed by Enterococcus faecalis (18.0%) and Klebsiella spp (10.3%). The highest E coli susceptibility rates were to imipenem (93.0%-99.8%), amikacin (97.3%-99.5%), nitrofurantoin (96.7%-98.9%), and fosfomycin (95.3%-100%), and the lowest were to cefuroxime (67.8%-86.4%), ciprofloxacin (61.2%-69.8%), and co-trimoxazole (55.0%-65.5%). We highlight the overall high activity of imipenem, piperacillin-tazobactam, nitrofurantoin, and fosfomycin on isolates versus the low activity of fluoroquinolones, co-trimoxazole, or cephalosporins. The activity of amoxicillin-clavulanic acid and fosfomycin decreased significantly over the 7-year study period. CONCLUSIONS: Imipenem and piperacillin-tazobactam appear to be good options for the empiric treatment of UTI acquired in hospital or requiring hospitalization, whereas nitrofurantoin and fosfomycin can be first-choice antibiotics for the treatment of uncomplicated community-acquired cystitis. However, surveillance studies are required to detect resistance to these antibiotics, given that an increase in uropathogen resistance rates may contraindicate its future use in empiric UTI therapy.
BACKGROUND: We conducted a retrospective analysis on the identification and antibiogram of all bacteria isolated from urine samples with microbiological confirmation of urinary tract infection (UTI) in a Spanish reference hospital over a 7-year period. METHODS: A retrospective analysis was performed of the identification and antibiogram data. RESULTS: A total of 31,758 uropathogens were isolated. Escherichia coli accounted for the majority (55.2%) of these, followed by Enterococcus faecalis (18.0%) and Klebsiella spp (10.3%). The highest E coli susceptibility rates were to imipenem (93.0%-99.8%), amikacin (97.3%-99.5%), nitrofurantoin (96.7%-98.9%), and fosfomycin (95.3%-100%), and the lowest were to cefuroxime (67.8%-86.4%), ciprofloxacin (61.2%-69.8%), and co-trimoxazole (55.0%-65.5%). We highlight the overall high activity of imipenem, piperacillin-tazobactam, nitrofurantoin, and fosfomycin on isolates versus the low activity of fluoroquinolones, co-trimoxazole, or cephalosporins. The activity of amoxicillin-clavulanic acid and fosfomycin decreased significantly over the 7-year study period. CONCLUSIONS:Imipenem and piperacillin-tazobactam appear to be good options for the empiric treatment of UTI acquired in hospital or requiring hospitalization, whereas nitrofurantoin and fosfomycin can be first-choice antibiotics for the treatment of uncomplicated community-acquired cystitis. However, surveillance studies are required to detect resistance to these antibiotics, given that an increase in uropathogen resistance rates may contraindicate its future use in empiric UTI therapy.
Authors: B A Cunha; C B Cunha; B Lam; J Giuga; J Chin; V F Zafonte; S Gerson Journal: Eur J Clin Microbiol Infect Dis Date: 2017-02-02 Impact factor: 3.267
Authors: Andrea D Tyler; Richard Kirsch; Raquel Milgrom; Joanne M Stempak; Boyko Kabakchiev; Mark S Silverberg Journal: Inflamm Bowel Dis Date: 2016-04 Impact factor: 5.325
Authors: Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas Journal: Clin Microbiol Rev Date: 2016-04 Impact factor: 26.132
Authors: Javier Sánchez-Céspedes; Emma Sáez-López; N Frimodt-Møller; Jordi Vila; Sara M Soto Journal: Antimicrob Agents Chemother Date: 2015-05-26 Impact factor: 5.191
Authors: Sangeeta Sastry; Lloyd G Clarke; Hind Alrowais; Ashley M Querry; Kathleen A Shutt; Yohei Doi Journal: Antimicrob Agents Chemother Date: 2015-09-14 Impact factor: 5.191